Cargando…

A role for CD47 in the development of experimental colitis mediated by SIRPα(+)CD103(−) dendritic cells

Mesenteric lymph node (mLN) CD103 (αE integrin)(+) dendritic cells (DCs) induce regulatory T cells and gut tolerance. However, the function of intestinal CD103(−) DCs remains to be clarified. CD47 is the ligand of signal regulatory protein α (SIRPα) and promotes SIRPα(+) myeloid cell migration. We f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fortin, Genevieve, Raymond, Marianne, Van, Vu Quang, Rubio, Manuel, Gautier, Patrick, Sarfati, Marika, Franchimont, Denis
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737153/ https://www.ncbi.nlm.nih.gov/pubmed/19703989 http://dx.doi.org/10.1084/jem.20082805

Ejemplares similares

Reprogramming in vivo th17 into th17/th2 by Sirp-α dendritic cells in the lungs
por: Quang Van, Vu, et al.
Publicado: (2011)

CD47(Low) Status on CD4 Effectors Is Necessary for the Contraction/Resolution of the Immune Response in Humans and Mice
por: Van, Vu Quang, et al.
Publicado: (2012)

Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021)

The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021)

CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)

Membrane-Mediated Cooperative Interactions of CD47 and SIRPα
por: Li, Long, et al.
Publicado: (2023)

CD47 fusion protein targets CD172a(+) cells in Crohn’s disease and dampens the production of IL-1β and TNF
por: Baba, Nobuyasu, et al.
Publicado: (2013)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

CD47/SIRPα axis: bridging innate and adaptive immunity
por: van Duijn, Anneloes, et al.
Publicado: (2022)

Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
por: Lu, Quansheng, et al.
Publicado: (2020)

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
por: Zhang, Wenting, et al.
Publicado: (2020)

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
por: Jia, Xiao, et al.
Publicado: (2021)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
por: Liao, Haiqin, et al.
Publicado: (2022)

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
por: Bouwstra, Renée, et al.
Publicado: (2022)

Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
por: Luo, Xukai, et al.
Publicado: (2023)

The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era
por: Montero, Enrique, et al.
Publicado: (2023)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
por: Zhao, Pengcheng, et al.
Publicado: (2023)

SIRPα - CD47 axis regulates dendritic cell-T cell interactions and TCR activation during T cell priming in spleen
por: Autio, Anu, et al.
Publicado: (2022)

CD28 Co-Stimulation Down Regulates Th17 Development
por: Bouguermouh, Salim, et al.
Publicado: (2009)

Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma
por: Hutter, Gregor, et al.
Publicado: (2019)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy
por: Logtenberg, Meike E. W., et al.
Publicado: (2019)

Augmentation of CD47/SIRPα signaling protects cones in genetic models of retinal degeneration
por: Wang, Sean K., et al.
Publicado: (2021)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
por: Xiao, Amy, et al.
Publicado: (2022)

Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis
por: Hendriks, Mark A.J.M., et al.
Publicado: (2021)

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
por: Voets, Erik, et al.
Publicado: (2019)

Signal regulatory protein alpha (SIRPα) regulates the homeostasis of CD103(+)CD11b(+) DCs in the intestinal lamina propria
por: Scott, Charlotte L, et al.
Publicado: (2014)

Cd47 Ligation Selectively Downregulates Human Interleukin 12 Production
por: Armant, Myriam, et al.
Publicado: (1999)

IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells
por: Yu, Jifeng, et al.
Publicado: (2022)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

Novel CD47: SIRPα Dependent Mechanism for the Activation of STAT3 in Antigen-Presenting Cell
por: Toledano, Natan, et al.
Publicado: (2013)

Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
por: Zhang, Jin, et al.
Publicado: (2018)

Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors
por: Miller, Thomas W., et al.
Publicado: (2019)

Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy
por: Huang, Bo, et al.
Publicado: (2021)

Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
por: Qu, Tailong, et al.
Publicado: (2022)

Therapeutic modulation of the CD47-SIRPα axis in the pediatric tumor microenvironment: working up an appetite
por: Gupta, Ajay, et al.
Publicado: (2020)

Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
por: Behrens, Leonie M., et al.
Publicado: (2022)

Binding Mechanism of CD47 with SIRPα Variants and Its Antibody: Elucidated by Molecular Dynamics Simulations
por: Huang, Kaisheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mtb62pffqrfih6k14jtkqs5qns